Maze Therapeutics MAZE 深 沪
等待开盘 10-01 09:30:00 美东时间
27.285
+0.265
+0.98%
华盛通- 最 高27.99
- 今 开27.21
- 成交量 24.68万股
- 最 低 26.95
- 昨 收 27.02
- 总市值 15.16亿
- 52周最高 53.65
- 市盈率 静 --
- 换手率 0.44%
- 52周最低 21.95
- 委 比 86.81%
- 总股本 5554.92万
- 历史最高 53.65
- 量 比 0.33
- 振 幅 3.85%
- 历史最低 6.71
- 每 手 1
- 风险率 8.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
美股大行评级 | Muse热度发酵，Meta目标价获大幅升至875美元；闪迪获看好至2400美元，潜在升幅约27%
今日重点评级关注：Citizens：上调Quince Therapeutics评级至"跑赢大市"，目标价77美元；康托·菲茨杰拉德：维持塞德斯医疗"超配"评级，目标价从61美元升至72美元
09-23 15:30
BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target
BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $46 price target.
09-23 00:02
On Holding, Viking Therapeutics, Shopify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 1% on Monday. Shares of On Holding AG (NYSE:ONON) rose sharply after the company affirmed its FY26 sales guidance above estimates and issued third-quarter sales guidance above estimates. On Holding also announced a $1 billion stock buyb...
09-22 22:25
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
SCYNEXIS appoints Todd Minga, M.D., as Senior Vice President, Research & Development. Dr. Minga brings over 20 years of experience in kidney disease and rare disorders, previously serving as Vice President, Medical Affairs and Clinical Development at Akebia Therapeutics. His expertise will support SCYNEXIS in advancing its rare disease programs, including SCY-770 for ADPKD and SCY-247. Dr. Minga expressed excitement about contributing to the Comp...
09-15 12:00
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
Maze Therapeutics announced its participation in three upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026; the Citi 2026 Biopharma Back to School Summit on September 10, 2026; and the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. Live webcasts will be available on the company's website, www.mazetx.com, and archived for 60 days. Maze Therapeutics is a clinical-sta...
09-02 11:00
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target
BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $46 price target.
08-12 18:00
Maze Therapeutics Q2 EPS $(0.76) Misses $(0.73) Estimate
Maze Therapeutics (NASDAQ:MAZE) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $(0.73) by 4.11 percent. This is a 1.3 percent increase over losses of $(0.77) per share from the same period last year.
08-12 04:36
